Baker E, Morton A G, Tavill A S
Br J Haematol. 1980 Aug;45(4):607-20. doi: 10.1111/j.1365-2141.1980.tb07184.x.
Factors affecting iron efflux from the isolated perfused rat liver were studied following the intravenous administration of transferrin-(59)Fe or transferrin-(55)Fe administered to the rat from 1.5 h to 3.5 d before perfusion of the liver. The liver was perfused with rat red cells suspended either in rat plasma or Eagle's Basal Medium (EBM). The mean rate of efflux into a plasma pool containing normal iron and transferrin concentrations was 0.9% of the initial hepatic radioactive iron pool per hour. In EBM the average rate of efflux was 0.1%/h and this could be increased to the rate observed with plasma by the addition of apotransferrin. The rate of iron release from the liver in the presence of apotransferrin or other chelators was inversely proportional to the time of prelabelling. Maximal release rates were observed in livers perfused within 5 h of administering transferrin-(59)Fe to the rat. The effect of apotransferrin on efflux into EBM was concentration dependent. However, the maximum release of liver iron by apotransferrin occurred at physiological apotransferrin concentrations and addition of apotransferrin to plasma produced no increase in the rate of iron efflux. The stimulation of iron release in EBM caused by apotransferrin could be reversed by reducing the unsaturated iron binding capacity of the perfusate, either by addition of iron or removal of apotransferrin. However, increasing the iron concentration in the perfusate by the addition of iron-saturated transferrin without any reduction in the unsaturated iron binding capacity additionally increased iron release into plasma and EBM. This presumably reflects the exchange of plasma transferrin-(56)Fe for liver (59)Fe. Hence iron release measured in these studies represent the sum of two processes-net release of (59)Fe induced by apotransferrin and iron exchange between plasma and liver iron pools. Apotransferrin and desferrioxamine were equally effective, per unit iron binding capacity, in mobilizing liver iron, and may compete for the same parenchymal iron pool. This suggests that mobilization of iron by apotransferrin may depend solely on its ability to chelate ferric iron and not on a more specific ferroxidase activity or interaction with membrane receptors.
在给大鼠静脉注射转铁蛋白 -(59)铁或转铁蛋白 -(55)铁后1.5小时至3.5天,对分离的灌注大鼠肝脏进行灌注,研究影响铁流出的因素。肝脏用悬浮于大鼠血浆或伊格尔基础培养基(EBM)中的大鼠红细胞进行灌注。流入含有正常铁和转铁蛋白浓度的血浆池的平均流出率为每小时初始肝脏放射性铁池的0.9%。在EBM中,平均流出率为0.1%/小时,通过添加脱铁转铁蛋白,其可增加至血浆中观察到的流出率。在存在脱铁转铁蛋白或其他螯合剂的情况下,肝脏中铁的释放速率与预标记时间成反比。在给大鼠注射转铁蛋白 -(59)铁后5小时内灌注的肝脏中观察到最大释放速率。脱铁转铁蛋白对流入EBM的流出的影响是浓度依赖性的。然而,脱铁转铁蛋白使肝脏铁的最大释放发生在生理脱铁转铁蛋白浓度下,并且向血浆中添加脱铁转铁蛋白不会增加铁流出率。脱铁转铁蛋白引起的EBM中铁释放的刺激可通过添加铁或去除脱铁转铁蛋白来降低灌注液的不饱和铁结合能力而逆转。然而,通过添加铁饱和转铁蛋白增加灌注液中的铁浓度而不饱和铁结合能力没有任何降低,会额外增加铁向血浆和EBM中的释放。这大概反映了血浆转铁蛋白 -(56)铁与肝脏(59)铁的交换。因此,这些研究中测量的铁释放代表两个过程的总和——脱铁转铁蛋白诱导的(59)铁的净释放以及血浆和肝脏铁池之间的铁交换。每单位铁结合能力,脱铁转铁蛋白和去铁胺在动员肝脏铁方面同样有效,并且可能竞争相同的实质铁池。这表明脱铁转铁蛋白对铁的动员可能仅取决于其螯合三价铁的能力,而不取决于更特异的铁氧化酶活性或与膜受体的相互作用。